首页> 美国卫生研究院文献>Experimental Hematology Oncology >Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

【2h】

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

机译：西妥昔单抗和厄洛替尼与抗VEGF抗体贝伐单抗联合进行的EGFR双重阻断在晚期实体瘤中的应用：1期剂量递增三联体联合试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Patient characteristics

机译：患者特征

著录项

期刊名称 Experimental Hematology Oncology
作者
Vivek Subbiah; Ecaterina Ileana Dumbrava; Yunfang Jiang; Kyaw Z. Thein; Aung Naing; David S. Hong; Siqing Fu; Sarina A. Piha-Paul; Apostolia M. Tsimberidou; Filip Janku; Funda Meric-Bernstam; Razelle Kurzrock; Gerald Falchook;
展开▼
作者单位

展开▼
年(卷),期 2020(9),-1
年度 2020
页码 -1
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Dual EGFR blockade; Cetuximab; erlotinib and bevacizumab; Advanced solid tumors; Phase 1 dose escalation;

机译：EGFR双重阻断;西妥昔单抗;厄洛替尼和贝伐单抗;晚期实体瘤;第1阶段剂量递增;

相似文献

外文文献
中文文献
专利

1. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial [J] . Progress in Artificial Intelligence . 2020,第1期

机译：双EGFR封闭与西妥昔单抗和厄洛替尼结合在先进的实体瘤中的抗VEGF抗体贝伐单抗：1阶段剂量升级三重态组合试验
2. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial [J] . Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Experimental Hematology Oncology . 2020,第1期

机译：双EGFR封闭与西妥昔单抗和Erlotinib与先进的实体瘤中的抗VEGF抗体贝伐单抗结合：A相1剂量升级三重态组合试验
3. Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid?tumors [J] . Takashi Kojima, Kentaro Yamazaki, Ken Kato, Cancer science. . 2018,第10期

机译：yeace i-exalation试验ysy-exalation试验，抗EGFR抗体混合物，日本晚期固体患者肿瘤
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. Phase I dose‐escalation trial of Sym004 an anti‐EGFR antibody mixture in Japanese patients with advanced solid tumors [O] . Takashi Kojima, Kentaro Yamazaki, Ken Kato, 2018

机译：抗EGFR抗体混合物Sym004在日本晚期实体瘤患者的I期剂量递增试验
6. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial [O] . Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, 2020

机译：双EGFR封闭与西妥昔单抗和Erlotinib与先进的实体瘤中的抗VEGF抗体贝伐单抗结合：A相1剂量升级三重态组合试验

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

摘要

著录项

相似文献

相关主题

期刊订阅